Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pralatrexate

FDA-approved product (solution, intravenous), marketed as Folotyn, Pralatrexate.

Registered studies
44
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Pralatrexate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Mature T-cell and NK-cell non-Hodgkin lymphoma
  • Neoplasm
  • T-cell non-Hodgkin lymphoma
  • Unspecified peripheral T-cell lymphoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Folic acid analogues
FDA pharmacologic class
Folate Analog Metabolic Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli82.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

44registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pralatrexate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pralatrexate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma

    NCT07691450 · start 2027-01-03

    Registered record
    Registry ID
    NCT07691450
    Conditions
    Recurrent Anaplastic Large Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type; Recurrent Follicular Helper T-Cell Lymphoma, Follicular-Type; Recurrent Follicular Helper T-Cell Lymphoma, Not Otherwise Specified; Recurrent Hepatosplenic T-Cell Lymphoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma; Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified; Recurrent Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma; Recurrent Primary Cutaneous Gamma-Delta T-Cell Lymphoma; Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Enteropathy-Associated T-Cell Lymphoma; Refractory Follicular Helper T-Cell Lymphoma; Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type; Refractory Fo
    Interventions
    Azacitidine; Belinostat; Biospecimen Collection; Computed Tomography; FDG-Positron Emission Tomography; Fludeoxyglucose F-18; Positron Emission Tomography; Pralatrexate; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2027-01-03
    Completion
    2029-11-24
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Anaplastic Large Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type +14 more
    InterventionAzacitidine; Belinostat; Biospecimen Collection; Computed Tomography +5 more
    PhasePhase 1
    Registry statusNot yet recruiting

  • Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

    NCT07225985 · start 2026-04-27

    Registered record
    Registry ID
    NCT07225985
    Conditions
    Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions
    Bendamustine; Pralatrexate; Bone Marrow Aspiration; Bone Marrow Biopsy; Chest Radiography; Computed Tomography; Echocardiography Test; Lumbar Puncture; Magnetic Resonance Imaging; Multigated Acquisition Scan; Peripheral Blood Stem Cell Transplantation; Positron Emission Tomography; Questionnaire Administration; Total-Body Irradiation; Biospecimen Collection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-04-27
    Completion
    2030-11-15
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent T-Cell Non-Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma
    InterventionBendamustine; Pralatrexate; Bone Marrow Aspiration; Bone Marrow Biopsy +11 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

    NCT06671717 · start 2024-12

    Registered record
    Registry ID
    NCT06671717
    Conditions
    Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
    Interventions
    Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2024-12
    Completion
    2027-07
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
    InterventionPralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

    NCT06561048 · start 2024-10-02

    Registered record
    Registry ID
    NCT06561048
    Conditions
    Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Systemic Anaplastic Large Cell Lymphoma; Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell
    Interventions
    Soquelitinib; Belinostat; Pralatrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-10-02
    Completion
    2028-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype +3 more
    InterventionSoquelitinib; Belinostat; Pralatrexate
    PhasePhase 3
    Registry statusRecruiting

  • To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

    NCT06072131 · start 2023-10-04

    Registered record
    Registry ID
    NCT06072131
    Conditions
    Peripheral T Cell Lymphoma
    Interventions
    Belinostat Injection; Pralatrexate Injection; CHOP; COP
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-10-04
    Completion
    2030-11
    Enrolment
    504

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T Cell Lymphoma
    InterventionBelinostat Injection; Pralatrexate Injection; CHOP; COP
    PhasePhase 3
    Registry statusRecruiting

  • Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

    NCT07036133 · start 2022-12-28

    Registered record
    Registry ID
    NCT07036133
    Conditions
    Advanced Solid Tumors; Hematologic Malignancies
    Interventions
    Pralatrexate Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2022-12-28
    Completion
    2027-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors; Hematologic Malignancies
    InterventionPralatrexate Injection
    PhasePhase 1
    Registry statusRecruiting

  • Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

    NCT03240211 · start 2022-02-02

    Registered record
    Registry ID
    NCT03240211
    Conditions
    PTCL; CTCL
    Interventions
    Pembrolizumab; Pralatrexate; Decitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2022-02-02
    Completion
    2026-05-25
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPTCL; CTCL
    InterventionPembrolizumab; Pralatrexate; Decitabine
    PhasePhase 1
    Registry statusActive not recruiting

  • Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

    NCT04747236 · start 2021-02-19

    Registered record
    Registry ID
    NCT04747236
    Conditions
    PTCL
    Interventions
    Azacytidine; Romidepsin; Belinostat; Pralatrexate; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-02-19
    Completion
    2030-06-02
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPTCL
    InterventionAzacytidine; Romidepsin; Belinostat; Pralatrexate +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

    NCT03719105 · start 2019-03-01

    Registered record
    Registry ID
    NCT03719105
    Conditions
    NK-Cell Lymphoma; NK-Cell Leukemia; Peripheral T Cell Lymphoma
    Interventions
    Methotrexate; pralatraxate,; Ifosfamide; Dexamethasone; Etoposide; calaspargase pegol; cyclophosphamide; Doxorubicin; Prednisone; Brentuximab Vedotin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2019-03-01
    Completion
    2028-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNK-Cell Lymphoma; NK-Cell Leukemia; Peripheral T Cell Lymphoma
    InterventionMethotrexate; pralatraxate,; Ifosfamide; Dexamethasone +6 more
    PhaseEarly phase 1
    Registry statusRecruiting

  • Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

    NCT03598998 · start 2019-02-04

    Registered record
    Registry ID
    NCT03598998
    Conditions
    Anaplastic Large Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Hepatosplenic T-Cell Lymphoma; Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma; Recurrent Mycosis Fungoides; Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Anaplastic Large Cell Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Enteropathy-Associated T-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Hepatosplenic T-Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified; Subcutaneous Panniculitis-Like T-Cell Lymphoma
    Interventions
    Pembrolizumab; Pralatrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2019-02-04
    Completion
    2027-02-18
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Large Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma +16 more
    InterventionPembrolizumab; Pralatrexate
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

    NCT03355768 · start 2018-09-01

    Registered record
    Registry ID
    NCT03355768
    Conditions
    Lymphoma, T-Cell, Peripheral
    Interventions
    Romidepsin; Pralatrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2018-09-01
    Completion
    2018-11-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, T-Cell, Peripheral
    InterventionRomidepsin; Pralatrexate
    PhasePhase 3
    Registry statusWithdrawn

  • Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

    NCT03161223 · start 2018-05-30

    Registered record
    Registry ID
    NCT03161223
    Conditions
    Lymphoma, T-Cell
    Interventions
    Durvalumab; Pralatrexate; Romidepsin; 5-Azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2018-05-30
    Completion
    2023-02
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, T-Cell
    InterventionDurvalumab; Pralatrexate; Romidepsin; 5-Azacitidine
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma

    NCT03356678 · start 2016-09-23

    Registered record
    Registry ID
    NCT03356678
    Conditions
    Relapsed or Refractory Peripheral T-cell Lymphoma
    Interventions
    Pralatrexate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-09-23
    Completion
    2017-06-30
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Peripheral T-cell Lymphoma
    InterventionPralatrexate
    PhaseNot recorded
    Registry statusCompleted

  • A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy

    NCT03150602 · start 2016-08-30

    Registered record
    Registry ID
    NCT03150602
    Conditions
    Peripheral T Cell Lymphoma; Progression, Disease
    Interventions
    Pralatrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-08-30
    Completion
    2020-12-31
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T Cell Lymphoma; Progression, Disease
    InterventionPralatrexate
    PhasePhase 4
    Registry statusUnknown

  • A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

    NCT02594267 · start 2015-11-10

    Registered record
    Registry ID
    NCT02594267
    Conditions
    Peripheral T-Cell Lymphoma (PTCL)
    Interventions
    Pralatrexate Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-11-10
    Completion
    2020-10-08
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T-Cell Lymphoma (PTCL)
    InterventionPralatrexate Injection
    PhasePhase 1
    Registry statusCompleted